Raltegravir with optimized background therapy for resistant HIV-1 infection.

By R. Steigbigel, D. Cooper, Princy N. Kumar, J. Eron, M. Schechter, M. Markowitz, M. Loutfy, J. Lennox, J. Gatell, J. Rockstroh and 19 more. New England Journal of Medicine, 2008

653 citations recorded by the source corpus.

Subfields: Infectious Diseases, Oncology, Virology

View Paper: https://www.semanticscholar.org/paper/ba6cb545806b4ff2f30f6689b87aad86dd5b9148

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. De Clercq

Citations in the corpus

• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. (2009, background): “It has proven highly effective in reducing viral loads in HIV-infected patients [25–27].”